NYSE:ALB - Albemarle Stock Price, Forecast & News

Albemarle's stock was trading at $70.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALB shares have decreased by 21.5% and is now trading at $55.02. View which stocks have been mosted impacted by Coronavirus.

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albemarle in the last year. There are currently 4 sell ratings, 12 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Albemarle.

Albemarle is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Albemarle.

Albemarle Co. (NYSE:ALB) announced its quarterly earnings data on Wednesday, February, 19th. The specialty chemicals company reported $1.73 earnings per share for the quarter, missing the consensus estimate of $1.75 by $0.02. The specialty chemicals company earned $992.60 million during the quarter, compared to the consensus estimate of $1.01 billion. Albemarle had a net margin of 14.86% and a return on equity of 16.12%. Albemarle's revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.53 EPS. View Albemarle's earnings history.

Albemarle declared a quarterly dividend on Friday, February 28th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.385 per share on Wednesday, April 1st. This represents a $1.54 annualized dividend and a yield of 2.80%. The ex-dividend date is Thursday, March 12th. This is a positive change from Albemarle's previous quarterly dividend of $0.37. View Albemarle's dividend history.

Albemarle issued an update on its FY20 earnings guidance on Wednesday, February, 19th. The company provided EPS guidance of $4.80-5.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.96. The company issued revenue guidance of $3.48-3.53, compared to the consensus revenue estimate of $3.53 billion.

25 Wall Street analysts have issued 12 month price objectives for Albemarle's stock. Their forecasts range from $39.50 to $116.00. On average, they expect Albemarle's stock price to reach $83.46 in the next year. This suggests a possible upside of 51.7% from the stock's current price. View analysts' price targets for Albemarle.

News coverage about ALB stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Albemarle earned a news impact score of 1.2 on InfoTrie's scale. They also assigned news headlines about the specialty chemicals company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutAlbemarle.

Albemarle saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 15,840,000 shares, a decline of 6.9% from the February 13th total of 17,010,000 shares. Based on an average trading volume of 1,890,000 shares, the days-to-cover ratio is currently 8.4 days. Approximately 15.0% of the company's stock are short sold. View Albemarle's Current Options Chain.

Some companies that are related to Albemarle include Ecolab (ECL), Sherwin-Williams (SHW), International Flavors & Fragrances (IFF), Celanese (CE), RPM International (RPM), NewMarket (NEU), Balchem (BCPC), Ashland Global (ASH), W. R. Grace & Co (GRA), Quaker Chemical (KWR), Stepan (SCL), Sensient Technologies (SXT), Innospec (IOSP), PolyOne (POL) and HB Fuller (FUL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Albemarle investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), AbbVie (ABBV), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX) and Valeant Pharmaceuticals Intl (VRX).

Albemarle trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALB."

Albemarle's stock is owned by many different institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (8.80%), Franklin Resources Inc. (8.81%), State Street Corp (7.04%), Baillie Gifford & Co. (4.19%), Bank of New York Mellon Corp (2.32%) and Geode Capital Management LLC (1.58%). Company insiders that own Albemarle stock include Deeanne J Marlow, Eric Norris, Karen G Narwold, Luther C Iv Kissam and Scott Tozier. View institutional ownership trends for Albemarle.

ALB stock was sold by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Bank of America Corp DE, AXA, CIBC Private Wealth Group LLC, Janus Henderson Group PLC, Franklin Resources Inc., Franklin Resources Inc., and Handelsbanken Fonder AB. Company insiders that have sold Albemarle company stock in the last year include Karen G Narwold, Luther C Iv Kissam, and Scott Tozier. View insider buying and selling activity for Albemarle.

ALB stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Eagle Asset Management Inc., State Street Corp, Bank of New York Mellon Corp, Amundi Pioneer Asset Management Inc., Nuveen Asset Management LLC, Baillie Gifford & Co., and Westwood Holdings Group Inc.. Company insiders that have bought Albemarle stock in the last two years include Deeanne J Marlow, and Eric Norris. View insider buying and selling activity for Albemarle.

Shares of ALB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALB stock can currently be purchased for approximately $55.02.

Albemarle has a market capitalization of $5.84 billion and generates $3.59 billion in revenue each year. The specialty chemicals company earns $533.23 million in net income (profit) each year or $6.04 on an earnings per share basis. Albemarle employs 6,000 workers across the globe. View additional information about Albemarle.

The official website for Albemarle is http://www.albemarle.com/.

Albemarle's mailing address is 4250 CONGRESS STREET SUITE 900, CHARLOTTE NC, 28209. The specialty chemicals company can be reached via phone at 980-299-5700 or via email at [email protected]